Analysts await Diplomat Pharmacy, Inc. (NASDAQ:DPLO) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $0.18 EPS, up 50% or $0.09 from last year’s $0.09 per share.

At the moment 11 analysts are watching Diplomat Pharmacy, Inc. (NASDAQ:DPLO), 4 rate it “Buy”, 2 “Outperform”, 5 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 9 analysts have a mean sales target of 1,103.77 million. For the quarter ending Sep-16, 9 analysts have a mean sales target of 1,190.85 million whilst for the year ending Dec-16, 11 analysts have a mean target of 4,513.39 million.

In terms of earnings per share, 11 analysts have a 0.22 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 11 analysts have a 0.24 EPS mean target and for the quarter ending Sep-16 there are 11 estimates of 0.88 EPS.

The biggest institutional shareholders in Diplomat Pharmacy, Inc. include Janus Capital Management LLC which owns 6 million shares in the company valued at $175.12 million. T. Rowe Price Associates, Inc. is the second biggest holder with 5 million shares currently valued at 177.14 million whilst AllianceBernstein LP has 3 million shares valued at 97.90 million.

Total shares held by institutions as of the most recent company filings are 50,566,719 with a reported 6,950,497 bought and 1,951,461 sold. These holdings make up 78.39% of the company’s outstanding shares.

Currently insiders hold 1,197,150 shares in the business which makes up 1.86% of shares. The biggest holder currently is Mr. Jeffrey M. Rowe who owns 1,000,284 shares (1.55% of those outstanding), whilst Sean M. Whelan holds 142,530 (0.22% of shares outstanding) and Kenneth O. Klepper holds 38,731 (0.06% of shares outstanding).

The stock decreased 1.85% or $0.54 during the last trading session, hitting $36.66. Diplomat Pharmacy, Inc. (NASDAQ:DPLO) has risen 4.04% over the past 6 months and is uptrending.